The incidence of K-ras mutations has been reported to be higher in CC patients with lymph node metastasis than in those without lymph node metastasis but no significant correlation with survival has found [4, 6, 20]. The gene discussed is KRAS; the disease is metastatic malignant neoplasm in the lymph nodes.